Navigation Links
Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting
Date:3/17/2009

REINACH, Switzerland, March 17 /PRNewswire-FirstCall/ -- In their press release of 25 February 2009, Arpida communicated that the Board of Directors was in the process of reviewing all the options for the company's future.

In preparation of the shareholders' meeting on 7 May 2009, the Board wishes to update shareholders as follows: At the shareholders' meeting, the Board plans to present all available strategic choices, which could include the following options or a combination thereof:

    - reverse merger with another biotech business
    - selling iclaprim and related assets
    - tender offer for the entire company
    - other options, including a return of capital

The Board believes that the currently depressed stock market may value the company as a whole less than the sum of its assets. It will therefore invite Arpida shareholders to select their preferred strategic option at the shareholders' meeting on 7 May 2009.

The invitation and agenda for the AGM will be available from 15 April 2009.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:

    Dr Jurgen Raths, President and CEO
    Tel.: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel.: +41-61-417-96-65
'/>"/>
SOURCE  Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 ... tracking to reporting eLearning solution using Tin Can ... and dashboard tool. CLD is a leading developer ... and medical device companies worldwide. , Tin ... standard that helps learners and trainers more accurately ...
(Date:5/21/2013)... 21, 2013 Alpha Source, Inc., ... will be exhibiting for the 13th consecutive year ... Instrumentation (AAMI) 2013 Conference and Expo. The conference ... and manufacture healthcare technologies. This year’s event will ... California. , The three-day event draws over ...
(Date:5/21/2013)... Clinverse, Inc. , a ... trials, announced today it has formed a strategic ... ClinPay® FLS eClinical commerce platform aggregates data collected ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship product, ... reporting transfer of value at investigator meetings or ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
... Quark Pharmaceuticals, Inc.,a development-stage pharmaceutical company ... therapeutics, today announced the,presentation of posters ... taking place,September 16-18, 2008 in Stockholm, ... Hagar Kalinski, and Hagit Ashush, presented ...
... 17 Dendreon Corporation,(Nasdaq: DNDN ) today announced ... of Dendreon, will present a company update at the,UBS ... Monday, September,22, 2008 at 1:30 p.m. ET., A ... through the,Investor Relations section of the Dendreon website, http://www.dendreon.com ...
... China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, ... the "Company"), one of the leading plasma-based ... ("PRC"), today announced that the Company,received approval ... Administration (the,"SFDA") to commence clinical trial of ...
Cached Biology Technology:Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... of plants genetically tweaked to absorb more contaminants, researchers ... wild-type counterparts. The results raised hopes that the plants ... soil. , The new research findings, published Feb. 1 ... three transgenic lines of the Indian mustard plant, Brassica ...
... of Cell Metabolism has provided insight into a key ... suggests a novel approach to the development of cholesterol-lowering ... of the most prescribed cholesterol inhibitors, according to researchers ... Cells obtain cholesterol, an important component of cell membranes, ...
... Washington Alaska Salmon Program, the world's longest-running effort to ... million from the Gordon and Betty Moore Foundation to ... program has applications for Pacific salmon all along the ... salmon runs and their management. , The grant boosts ...
Cached Biology News:Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4Insight into natural cholesterol control suggests novel cholesterol-lowering therapy 2Alaskan puzzles, monitoring provide insight about North Pacific salmon runs 2
DTT 50 l...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: